Anesthesia & Life Support in Minnesota

Forj Medical is a global contract design and manufacturing organization (CDMO) specializing in advanced medical device development and high-volume manufacturing. The company operates 450,000+ square feet of manufacturing space across six global facilities (U.S., Costa Rica, Singapore, Indonesia) and assembles 250+ million devices and components annually. Core competencies include electromagnetic sensors and navigation systems, surgical energy systems, fluid and gas management solutions, optical systems, stimulation and active wearables, and consumables and components. Forj Medical provides end-to-end services from concept and full medical device system development through commercialization, including custom electromechanical system design, design for manufacturing (DFM), design for automation and scale, custom prototyping, and process and test development. Manufacturing capabilities are vertically integrated, encompassing PCBA manufacturing, precision molding, cable assembly, cleanroom operations, polymer and metal 3D printing, and automation. The company maintains ISO 13485 certification and holds five FDA Establishment Registrations. Quality management systems include robust QMS, traceability protocols, risk management, and audit readiness. Supply chain and operational services include supply chain management, service and maintenance, sustaining engineering, packaging and shipping, and international logistics. Clients span Fortune 500 medical device manufacturers and emerging medtech companies. The organization combines 4+ million combined hours of medical device engineering expertise across its portfolio.

ThermaSolutions LLC is a global leader in hyperthermic cancer treatment systems, headquartered in White Bear Lake, Minnesota. The company manufactures and distributes the ThermoChem HT series (HT-2000 and HT-2500) of integrated hyperthermic intraperitoneal chemotherapy (HIPEC) devices for adjunctive surgical oncology. These systems heat and circulate perfusate solutions to therapeutic temperatures (42–43°C) within the intraperitoneal cavity during cytoreductive surgery for peritoneal surface malignancies, including pseudomyxoma peritonei and ovarian cancer. ThermaSolutions also offers the HurriChem device line—FDA-approved (HurriChem Device Kit for laparoscopic irrigation) and CE-marked (HurriChem Nebulizer for pressurized intraperitoneal chemotherapy/PIPAC)—which aerosolizes fluids for delivery via minimally invasive ports during laparoscopic procedures. Additional product offerings include disposable HIPEC procedure kits, whole-body hyperthermia systems (HEATT, in partnership with Verthermia), isolated limb perfusion products, the SurgiChem Dual Injector Pump, thermal insulators, lasso tubing drains, and chemo waste management products. The company maintains FDA 510(k) clearance for select devices and CE marking for international markets. ThermaSolutions provides comprehensive training, clinical support, and educational resources through the HIPEC Program Support initiative and partnerships with oncology organizations. Founded in 1999, the company operates a US headquarters in White Bear Lake, MN, and an international office in Breda, The Netherlands, serving hospitals and surgical centers globally through a distributor network.

Resolution Medical is a medical device development and manufacturing partner specializing in complex catheter delivery systems, active implantable devices, and component manufacturing. The company serves structural heart, cardiology, vascular, heart failure (VAD), neuromodulation, electrophysiology, and additional specialty markets including ENT, neurology, urology, oncology, endoscopy, and robotics. Core capabilities span the full product lifecycle: concept and design development, BioSimulation and testing with cardiovascular visualization in pressurized heart models, New Product Introduction (NPI) with design-for-manufacturing optimization, and end-to-end manufacturing from prototyping through commercial production. Resolution Medical operates specialized clean rooms, sterile packaging, labeling, and distribution infrastructure. In structural heart, the company develops implants and catheter delivery systems for mitral, tricuspid, aortic, and pulmonary valve interventions, as well as shunts, stents, closure devices, and embolic protection. Cardiology and vascular expertise includes complex delivery platforms, imaging and sensing catheter systems for peripheral, neurovascular, and cardiovascular applications, DVT/PE management, drug delivery, and flow management. Heart failure capabilities encompass VAD pump development, drivelines, and deployment systems. Neuromodulation focus includes Class III active implantables: implantable pulse generators (IPGs), leads, headers, adapters, and subassemblies for spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and peripheral nerve modulation. Electrophysiology specialization covers diagnostic mapping and energy delivery catheters with modalities including pulsed field ablation (PFA), RF energy, cryotherapy, and vapor therapy. The company maintains a quality management system per ISO 13485:2016 and operates under FDA guidelines. Resolution Medical was recently acquired by Resonetics (2025) and operates with 100+ engineers backed by 1,000+ combined years of experience.

Hemostasis, LLC is a FDA-registered, ISO 13485:2016-certified medical device manufacturer specializing in advanced biomaterial-based hemostasis and wound-healing technologies. The company develops and manufactures innovative bleeding-control products utilizing pharmaceutical-grade NOCC chitosan polymer technology. Core offerings include PosiSep® branded hemostat dressings and intranasal splints for ENT sinus procedures, NexStat® and Accel® topical hemostatic powders, BleedArrest® foam sponges, BoneSeal® bone hemostats, and NexFoam® topical hemostat sponges. Products are designed for diverse surgical applications including sinus, cardiac, orthopedic, vascular, soft tissue, and solid organ procedures. The company provides custom manufacturing services for OEMs and maintains active research and development capabilities in bleeding control technologies.

NeuroOne Medical Technologies develops minimally invasive diagnostic and therapeutic neurosurgical devices based on proprietary thin-film electrode technology. The company's primary platform enables high-definition neuronal recording and ablation for functional neurosurgery, with an initial focus on epilepsy and trigeminal neuralgia treatment. Core products include the OneRF® Radiofrequency Ablation System (FDA-cleared K231675 for functional neurosurgical procedures; K251243 for trigeminal nerve ablation), which uniquely performs both diagnostic mapping and therapeutic ablation using the same stereotactic electroencephalography (sEEG) electrode. The Evo® sEEG System (FDA-cleared K222404) provides temporary subsurface brain recording, monitoring, and stimulation, while the Evo® Cortical Electrodes (FDA-cleared K192764) offer surface brain recording with reduced immunological response and improved cable management. NeuroOne's flexible thin-film electrode platform is designed to provide higher-resolution neural signal acquisition compared to conventional rigid electrodes, potentially reducing infection risk and procedure complexity. The company is developing a comprehensive portfolio for neurological applications beyond epilepsy, working with leading neurosurgical centers including Mayo Clinic. All devices are subject to federal restriction to sale by or on the order of a physician.

Solo Pace Inc manufactures temporary pacing technology and systems engineered specifically for transcatheter heart valve (THV) procedures. The company specializes in precision pacing solutions that provide confident control during valve deployment while reducing patient risk. Product lines include the SoloPace CONTROL™ System, an innovative pacing platform designed to reduce pacing risk and improve procedural efficiency during THV interventions, and the SoloPace FUSION™ System, a fully integrated sterile kit that combines temporary intracardiac pacing with streamlined THV device delivery. These solutions address a critical clinical need in structural heart interventions where reliable, precise temporary pacing is essential during transcatheter aortic valve replacement (TAVR) and other valve procedures. The company serves interventional cardiologists, structural heart specialists, and cardiac catheterization laboratories. Solo Pace's products are designed for hospital-based cardiac catheterization and hybrid operating room environments. Specific regulatory certifications and manufacturing details are not provided on the available website content.